



Clinical trial results:

A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)

Summary

| | |
|--------------------------|--|
| EudraCT number | 2017-000574-11 |
| Trial protocol | IE GB DE HU AT LT CZ NL SK BG GR PL BE ES PT EE HR IT RO |
| Global end of trial date | 13 December 2023 |

Results information

| | |
|--------------------------------|--------------|
| Result version number | v1 (current) |
| This version publication date | 09 June 2024 |
| First version publication date | 09 June 2024 |

Trial information

Trial identification

| | |
|-----------------------|------------|
| Sponsor protocol code | SHP647-304 |
|-----------------------|------------|

Additional study identifiers

| | |
|------------------------------------|-------------|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT03283085 |
| WHO universal trial number (UTN) | - |

Notes:

Sponsors

| | |
|------------------------------|--|
| Sponsor organisation name | Shire |
| Sponsor organisation address | 300 Shire Way, Lexington, United States, MA 02421 |
| Public contact | Study Director, Shire, N/A +1 866-8425335, ClinicalTransparency@shire.com |
| Scientific contact | Study Director, Shire, N/A +1 866-8425335, ClinicalTransparency@shire.com |

Notes:

Paediatric regulatory details

| | |
|--|-----|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | Yes |

Notes:

Results analysis stage

| | |
|--|------------------|
| Analysis stage | Final |
| Date of interim/final analysis | 13 December 2023 |
| Is this the analysis of the primary completion data? | No |

| | |
|----------------------------------|------------------|
| Global end of trial reached? | Yes |
| Global end of trial date | 13 December 2023 |
| Was the trial ended prematurely? | No |

Notes:

General information about the trial

Main objective of the trial:

The main purpose of this study is to evaluate the safety and tolerability of long-term treatment with ontamalimab in participants with moderate to severe UC or CD.

Protection of trial subjects:

Each participant signed an informed consent form (ICF) before participating in the study.

Background therapy: -

Evidence for comparator: -

| | |
|---|------------------|
| Actual start date of recruitment | 27 February 2018 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | No |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|---------------------------|
| Country: Number of subjects enrolled | South Africa: 11 |
| Country: Number of subjects enrolled | Spain: 5 |
| Country: Number of subjects enrolled | Ukraine: 66 |
| Country: Number of subjects enrolled | United Kingdom: 5 |
| Country: Number of subjects enrolled | United States: 52 |
| Country: Number of subjects enrolled | Argentina: 1 |
| Country: Number of subjects enrolled | Australia: 12 |
| Country: Number of subjects enrolled | Austria: 5 |
| Country: Number of subjects enrolled | Belgium: 3 |
| Country: Number of subjects enrolled | Bosnia and Herzegovina: 3 |
| Country: Number of subjects enrolled | Bulgaria: 20 |
| Country: Number of subjects enrolled | Canada: 3 |
| Country: Number of subjects enrolled | Colombia: 3 |
| Country: Number of subjects enrolled | Croatia: 11 |
| Country: Number of subjects enrolled | Czechia: 15 |
| Country: Number of subjects enrolled | Estonia: 1 |
| Country: Number of subjects enrolled | Germany: 1 |
| Country: Number of subjects enrolled | Greece: 1 |
| Country: Number of subjects enrolled | Hungary: 24 |
| Country: Number of subjects enrolled | Ireland: 1 |
| Country: Number of subjects enrolled | Israel: 3 |
| Country: Number of subjects enrolled | Italy: 22 |

| | |
|--------------------------------------|------------------------|
| Country: Number of subjects enrolled | Japan: 25 |
| Country: Number of subjects enrolled | Korea, Republic of: 16 |
| Country: Number of subjects enrolled | Lebanon: 1 |
| Country: Number of subjects enrolled | Lithuania: 3 |
| Country: Number of subjects enrolled | Mexico: 14 |
| Country: Number of subjects enrolled | Netherlands: 5 |
| Country: Number of subjects enrolled | New Zealand: 2 |
| Country: Number of subjects enrolled | Poland: 146 |
| Country: Number of subjects enrolled | Portugal: 7 |
| Country: Number of subjects enrolled | Romania: 9 |
| Country: Number of subjects enrolled | Russian Federation: 43 |
| Country: Number of subjects enrolled | Serbia: 1 |
| Country: Number of subjects enrolled | Slovakia: 17 |
| Worldwide total number of subjects | 557 |
| EEA total number of subjects | 296 |

Notes:

| Subjects enrolled per age group | |
|---|-----|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 11 |
| Adults (18-64 years) | 512 |
| From 65 to 84 years | 34 |
| 85 years and over | 0 |

Subject disposition

Recruitment

Recruitment details:

Participants took part in the study at 225 investigative sites in 33 countries from 27 February 2018 to 13 December 2023.

Pre-assignment

Screening details:

Participants from induction and maintenance studies of ulcerative colitis (UC) [SHP647-301 (NCT03259334), SHP647-302 (NCT03259308), and SHP647-303 (NCT03290781)] and Crohn's disease (CD) [SHP647-305 (NCT03559517), SHP647-306 (NCT03566823), and SHP647-307 (NCT03627091)] were enrolled to receive either 25 milligrams (mg) or 75 mg ontamalimab.

Period 1

| | |
|------------------------------|--------------------------------|
| Period 1 title | Overall Study (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Randomised - controlled |
| Blinding used | Double blind |
| Roles blinded | Subject, Investigator |

Arms

| | |
|------------------------------|-----------------------|
| Are arms mutually exclusive? | Yes |
| Arm title | UC: Ontamalimab 25 mg |

Arm description:

Participants received 25 milligrams (mg) of ontamalimab solution for injection subcutaneously (SC), every 4 weeks (Q4W), for up to 3 years

| | |
|--|------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | Ontamalimab 25 mg |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

Ontamalimab 25 mg, subcutaneously (SC), every 4 weeks (Q4W)

| | |
|------------------|---------------------------------|
| Arm title | UC: Ontamalimab 25mg then 75 mg |
|------------------|---------------------------------|

Arm description:

Participants received 25 mg of ontamalimab solution for injection SC, Q4W, and later progressed to receive 75 mg in a similar manner for up to 5.79 years.

| | |
|--|------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | Ontamalimab 75 mg |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

Ontamalimab 75 mg, subcutaneously (SC), every 4 weeks (Q4W)

| | |
|--|------------------------|
| Investigational medicinal product name | Ontamalimab 25 mg |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

Ontamalimab 25 mg, subcutaneously (SC), every 4 weeks (Q4W)

| | |
|------------------|----------------------|
| Arm title | UC: Ontamalimab 75mg |
|------------------|----------------------|

Arm description:

Participants received 75 mg of ontamalimab solution for injection SC, Q4W, for up to 5.79 years.

| | |
|--|------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | Ontamalimab 75 mg |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

Ontamalimab 75 mg, subcutaneously (SC), every 4 weeks (Q4W)

| | |
|------------------|-----------------------|
| Arm title | CD: Ontamalimab 25 mg |
|------------------|-----------------------|

Arm description:

Participants received 25 mg of ontamalimab solution for injection SC, Q4W, for up to 3 years.

| | |
|--|------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | Ontamalimab 25 mg |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

Ontamalimab 25 mg, subcutaneously (SC), every 4 weeks (Q4W)

| | |
|------------------|----------------------------------|
| Arm title | CD: Ontamalimab 25 mg then 75 mg |
|------------------|----------------------------------|

Arm description:

Participants received 25 mg of ontamalimab solution for injection SC, Q4W, and later progressed to receive 75 mg in a similar manner for up to 5.79 years.

| | |
|--|------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | Ontamalimab 75 mg |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

Ontamalimab 75 mg, subcutaneously (SC), every 4 weeks (Q4W)

| | |
|--|------------------------|
| Investigational medicinal product name | Ontamalimab 25 mg |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

Ontamalimab 25 mg, subcutaneously (SC), every 4 weeks (Q4W)

| | |
|------------------|-----------------------|
| Arm title | CD: Ontamalimab 75 mg |
|------------------|-----------------------|

Arm description:

Participants received 75 mg of ontamalimab solution for injection SC, Q4W, for up to 5.79 years.

| | |
|----------|--------------|
| Arm type | Experimental |
|----------|--------------|

| | |
|--|------------------------|
| Investigational medicinal product name | Ontamalimab 75 mg |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

Ontamalimab 75 mg, subcutaneously (SC), every 4 weeks (Q4W)

| Number of subjects in period 1 | UC: Ontamalimab 25 mg | UC: Ontamalimab 25mg then 75 mg | UC: Ontamalimab 75mg |
|--------------------------------|-----------------------|---------------------------------|----------------------|
| Started | 89 | 159 | 268 |
| Completed | 0 | 117 | 129 |
| Not completed | 89 | 42 | 139 |
| Adverse event, serious fatal | - | - | 3 |
| Consent withdrawn by subject | 42 | 21 | 66 |
| Physician decision | 14 | 8 | 19 |
| Adverse event, non-fatal | 18 | 3 | 13 |
| Pregnancy | - | - | 1 |
| Site Terminated by Sponsor | 1 | - | 3 |
| Lost to follow-up | 2 | - | 2 |
| Reason not Specified | - | 4 | 8 |
| Lack of efficacy | 12 | 6 | 24 |

| Number of subjects in period 1 | CD: Ontamalimab 25 mg | CD: Ontamalimab 25 mg then 75 mg | CD: Ontamalimab 75 mg |
|--------------------------------|-----------------------|----------------------------------|-----------------------|
| Started | 5 | 10 | 26 |
| Completed | 0 | 6 | 12 |
| Not completed | 5 | 4 | 14 |
| Adverse event, serious fatal | 1 | - | - |
| Consent withdrawn by subject | 3 | 3 | 5 |
| Physician decision | - | - | 2 |
| Adverse event, non-fatal | - | - | 5 |
| Pregnancy | - | - | - |
| Site Terminated by Sponsor | - | - | - |
| Lost to follow-up | - | - | 1 |
| Reason not Specified | - | - | 1 |
| Lack of efficacy | 1 | 1 | - |

Baseline characteristics

Reporting groups

| | |
|--|----------------------------------|
| Reporting group title | UC: Ontamalimab 25 mg |
| Reporting group description: Participants received 25 milligrams (mg) of ontamalimab solution for injection subcutaneously (SC), every 4 weeks (Q4W), for up to 3 years | |
| Reporting group title | UC: Ontamalimab 25mg then 75 mg |
| Reporting group description: Participants received 25 mg of ontamalimab solution for injection SC, Q4W, and later progressed to receive 75 mg in a similar manner for up to 5.79 years. | |
| Reporting group title | UC: Ontamalimab 75mg |
| Reporting group description: Participants received 75 mg of ontamalimab solution for injection SC, Q4W, for up to 5.79 years. | |
| Reporting group title | CD: Ontamalimab 25 mg |
| Reporting group description: Participants received 25 mg of ontamalimab solution for injection SC, Q4W, for up to 3 years. | |
| Reporting group title | CD: Ontamalimab 25 mg then 75 mg |
| Reporting group description: Participants received 25 mg of ontamalimab solution for injection SC, Q4W, and later progressed to receive 75 mg in a similar manner for up to 5.79 years. | |
| Reporting group title | CD: Ontamalimab 75 mg |
| Reporting group description: Participants received 75 mg of ontamalimab solution for injection SC, Q4W, for up to 5.79 years. | |

| Reporting group values | UC: Ontamalimab 25 mg | UC: Ontamalimab 25mg then 75 mg | UC: Ontamalimab 75mg |
|------------------------------------|-----------------------|---------------------------------|----------------------|
| Number of subjects | 89 | 159 | 268 |
| Age Categorical Units: Subjects | | | |

| | | | |
|--|----|-----|-----|
| Gender categorical Units: Subjects | | | |
| Female | 29 | 67 | 111 |
| Male | 60 | 92 | 157 |
| Age categorical Units: Subjects | | | |
| <= 18 years | 0 | 2 | 7 |
| Between 18 and 65 | 87 | 148 | 239 |
| >= 65 years | 2 | 9 | 22 |
| Ethnicity (NIH/OMB) Units: Subjects | | | |
| Hispanic or Latino | 5 | 12 | 15 |
| Not Hispanic or Latino | 84 | 146 | 251 |
| Unknown or Not Reported | 0 | 1 | 2 |
| Race (NIH/OMB) Units: Subjects | | | |
| American Indian or Alaska Native | 0 | 2 | 4 |
| Asian | 7 | 14 | 24 |

| | | | |
|---|----|-----|-----|
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 0 |
| Black or African American | 0 | 2 | 4 |
| White | 77 | 135 | 231 |
| More than one race | 2 | 2 | 3 |
| Unknown or Not Reported | 2 | 4 | 2 |

| Reporting group values | CD: Ontamalimab 25 mg | CD: Ontamalimab 25 mg then 75 mg | CD: Ontamalimab 75 mg |
|------------------------|-----------------------|----------------------------------|-----------------------|
| Number of subjects | 5 | 10 | 26 |
| Age Categorical | | | |
| Units: Subjects | | | |

| | | | |
|---|---|---|----|
| Gender categorical | | | |
| Units: Subjects | | | |
| Female | 1 | 5 | 14 |
| Male | 4 | 5 | 12 |
| Age categorical | | | |
| Units: Subjects | | | |
| <= 18 years | 0 | 1 | 1 |
| Between 18 and 65 | 4 | 9 | 25 |
| >= 65 years | 1 | 0 | 0 |
| Ethnicity (NIH/OMB) | | | |
| Units: Subjects | | | |
| Hispanic or Latino | 0 | 1 | 2 |
| Not Hispanic or Latino | 5 | 9 | 24 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB) | | | |
| Units: Subjects | | | |
| American Indian or Alaska Native | 0 | 0 | 1 |
| Asian | 1 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 2 |
| White | 4 | 9 | 23 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 0 |

| Reporting group values | Total | | |
|------------------------|-------|--|--|
| Number of subjects | 557 | | |
| Age Categorical | | | |
| Units: Subjects | | | |

| | | | |
|--------------------|-----|--|--|
| Gender categorical | | | |
| Units: Subjects | | | |
| Female | 227 | | |
| Male | 330 | | |
| Age categorical | | | |
| Units: Subjects | | | |
| <= 18 years | 11 | | |
| Between 18 and 65 | 512 | | |
| >= 65 years | 34 | | |

| | | | |
|---|-----|--|--|
| Ethnicity (NIH/OMB) | | | |
| Units: Subjects | | | |
| Hispanic or Latino | 35 | | |
| Not Hispanic or Latino | 519 | | |
| Unknown or Not Reported | 3 | | |
| Race (NIH/OMB) | | | |
| Units: Subjects | | | |
| American Indian or Alaska Native | 7 | | |
| Asian | 46 | | |
| Native Hawaiian or Other Pacific Islander | 1 | | |
| Black or African American | 8 | | |
| White | 479 | | |
| More than one race | 7 | | |
| Unknown or Not Reported | 9 | | |

Subject analysis sets

| | |
|---|----------------------------------|
| Subject analysis set title | UC: Ontamalimab 25mg then 75 mg |
| Subject analysis set type | Full analysis |
| Subject analysis set description: | |
| Participants received 25 mg of ontamalimab solution for injection SC, Q4W, and later progressed to receive 75 mg in a similar manner for up to 3 years. | |
| Subject analysis set title | UC: Ontamalimab 75mg |
| Subject analysis set type | Full analysis |
| Subject analysis set description: | |
| Participants received 75 mg of ontamalimab solution for injection SC, Q4W, for up to 3 years. | |
| Subject analysis set title | CD: Ontamalimab 25 mg then 75 mg |
| Subject analysis set type | Full analysis |
| Subject analysis set description: | |
| Participants received 25 mg of ontamalimab solution for injection SC, Q4W, and later progressed to receive 75 mg in a similar manner for up to 3 years. | |
| Subject analysis set title | CD: Ontamalimab 75 mg |
| Subject analysis set type | Full analysis |
| Subject analysis set description: | |
| Participants received 75 mg of ontamalimab solution for injection SC, Q4W, for up to 3 years. | |

| Reporting group values | UC: Ontamalimab 25mg then 75 mg | UC: Ontamalimab 75mg | CD: Ontamalimab 25 mg then 75 mg |
|------------------------|------------------------------------|-------------------------|-------------------------------------|
| Number of subjects | 159 | 268 | 10 |
| Age Categorical | | | |
| Units: Subjects | | | |

| | | | |
|---------------------|---|---|---|
| Gender categorical | | | |
| Units: Subjects | | | |
| Female | 0 | 0 | 0 |
| Male | 0 | 0 | 0 |
| Age categorical | | | |
| Units: Subjects | | | |
| <= 18 years | 0 | 0 | 0 |
| Between 18 and 65 | 0 | 0 | 0 |
| >= 65 years | 0 | 0 | 0 |
| Ethnicity (NIH/OMB) | | | |

| | | | |
|---|---|---|---|
| Units: Subjects | | | |
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB) | | | |
| Units: Subjects | | | |
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |

| | | | |
|-------------------------------|--------------------------|--|--|
| Reporting group values | CD: Ontamalimab 75 mg | | |
| Number of subjects | 13 | | |
| Age Categorical | | | |
| Units: Subjects | | | |

| | | | |
|---|---|--|--|
| Gender categorical | | | |
| Units: Subjects | | | |
| Female | 0 | | |
| Male | 0 | | |
| Age categorical | | | |
| Units: Subjects | | | |
| <= 18 years | 0 | | |
| Between 18 and 65 | 0 | | |
| >= 65 years | 0 | | |
| Ethnicity (NIH/OMB) | | | |
| Units: Subjects | | | |
| Hispanic or Latino | 0 | | |
| Not Hispanic or Latino | 0 | | |
| Unknown or Not Reported | 0 | | |
| Race (NIH/OMB) | | | |
| Units: Subjects | | | |
| American Indian or Alaska Native | 0 | | |
| Asian | 0 | | |
| Native Hawaiian or Other Pacific Islander | 0 | | |
| Black or African American | 0 | | |
| White | 0 | | |
| More than one race | 0 | | |
| Unknown or Not Reported | 0 | | |

End points

End points reporting groups

| | |
|--|----------------------------------|
| Reporting group title | UC: Ontamalimab 25 mg |
| Reporting group description: Participants received 25 milligrams (mg) of ontamalimab solution for injection subcutaneously (SC), every 4 weeks (Q4W), for up to 3 years | |
| Reporting group title | UC: Ontamalimab 25mg then 75 mg |
| Reporting group description: Participants received 25 mg of ontamalimab solution for injection SC, Q4W, and later progressed to receive 75 mg in a similar manner for up to 5.79 years. | |
| Reporting group title | UC: Ontamalimab 75mg |
| Reporting group description: Participants received 75 mg of ontamalimab solution for injection SC, Q4W, for up to 5.79 years. | |
| Reporting group title | CD: Ontamalimab 25 mg |
| Reporting group description: Participants received 25 mg of ontamalimab solution for injection SC, Q4W, for up to 3 years. | |
| Reporting group title | CD: Ontamalimab 25 mg then 75 mg |
| Reporting group description: Participants received 25 mg of ontamalimab solution for injection SC, Q4W, and later progressed to receive 75 mg in a similar manner for up to 5.79 years. | |
| Reporting group title | CD: Ontamalimab 75 mg |
| Reporting group description: Participants received 75 mg of ontamalimab solution for injection SC, Q4W, for up to 5.79 years. | |
| Subject analysis set title | UC: Ontamalimab 25mg then 75 mg |
| Subject analysis set type | Full analysis |
| Subject analysis set description: Participants received 25 mg of ontamalimab solution for injection SC, Q4W, and later progressed to receive 75 mg in a similar manner for up to 3 years. | |
| Subject analysis set title | UC: Ontamalimab 75mg |
| Subject analysis set type | Full analysis |
| Subject analysis set description: Participants received 75 mg of ontamalimab solution for injection SC, Q4W, for up to 3 years. | |
| Subject analysis set title | CD: Ontamalimab 25 mg then 75 mg |
| Subject analysis set type | Full analysis |
| Subject analysis set description: Participants received 25 mg of ontamalimab solution for injection SC, Q4W, and later progressed to receive 75 mg in a similar manner for up to 3 years. | |
| Subject analysis set title | CD: Ontamalimab 75 mg |
| Subject analysis set type | Full analysis |
| Subject analysis set description: Participants received 75 mg of ontamalimab solution for injection SC, Q4W, for up to 3 years. | |

Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs)

| | |
|---|--|
| End point title | Number of Participants With Treatment Emergent Adverse Events (TEAEs) ^[1] |
| End point description: An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent AEs (TEAEs) were defined as AEs with start dates or worsening dates at the time of or following the first exposure to investigational product. The Safety Set included all participants who received at least 1 dose of IP in the SHP647-304 study. | |
| End point type | Primary |

End point timeframe:

From first dose of study drug up to end of study [EOS] (up to 5.79 years)

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis was planned for this endpoint.

| End point values | UC: Ontamalimab 25 mg | UC: Ontamalimab 25mg then 75 mg | UC: Ontamalimab 75mg | CD: Ontamalimab 25 mg |
|-----------------------------|-----------------------------|--|----------------------------|-----------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 89 | 159 | 268 | 5 |
| Units: participants | | | | |
| TEAE leading to death | 67 | 122 | 203 | 4 |

| End point values | CD: Ontamalimab 25 mg then 75 mg | CD: Ontamalimab 75 mg | | |
|-----------------------------|---|-----------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 10 | 26 | | |
| Units: participants | | | | |
| TEAE leading to death | 8 | 17 | | |

Statistical analyses

No statistical analyses for this end point

Primary: Number of Participants With Serious Infections

End point title Number of Participants With Serious Infections^[2]

End point description:

Serious infections were defined as any infections that were life-threatening or those requiring hospitalization or intravenous antibiotics based on the investigator's assessment. The Safety Set included all participants who received at least 1 dose of IP in the SHP647-304 study.

End point type Primary

End point timeframe:

From first dose of study drug up to EOS (up to 5.79 years)

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis was planned for this endpoint.

| End point values | UC: Ontamalimab 25 mg | UC: Ontamalimab 25mg then 75 mg | UC: Ontamalimab 75mg | CD: Ontamalimab 25 mg |
|-----------------------------|-----------------------------|--|----------------------------|-----------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 89 | 159 | 268 | 5 |
| Units: participants | 5 | 4 | 17 | 0 |

| | | | | |
|-----------------------------|---|-----------------------------|--|--|
| End point values | CD: Ontamalimab 25 mg then 75 mg | CD: Ontamalimab 75 mg | | |
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 10 | 26 | | |
| Units: participants | 0 | 0 | | |

Statistical analyses

No statistical analyses for this end point

Primary: Number of Participants With Notable Changes in Clinical Laboratory Parameters Over Time

| | |
|-----------------|--|
| End point title | Number of Participants With Notable Changes in Clinical Laboratory Parameters Over Time ^[3] |
|-----------------|--|

End point description:

Clinical laboratory assessments included hematology, serum chemistry and urinalysis. Any notable changes in the clinical laboratory value over time based on the investigator interpretation were reported. The Safety Set included all participants who received at least 1 dose of IP in the SHP647-304 study.

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

From first dose of study drug up to EOS (up to 5.79 years)

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis was planned for this endpoint.

| | | | | |
|-----------------------------|-----------------------------|--|----------------------------|-----------------------------|
| End point values | UC: Ontamalimab 25 mg | UC: Ontamalimab 25mg then 75 mg | UC: Ontamalimab 75mg | CD: Ontamalimab 25 mg |
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 89 | 159 | 268 | 5 |
| Units: participants | 0 | 0 | 0 | 0 |

| | | | | |
|-----------------------------|---|-----------------------------|--|--|
| End point values | CD: Ontamalimab 25 mg then 75 mg | CD: Ontamalimab 75 mg | | |
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 10 | 26 | | |
| Units: participants | 0 | 0 | | |

Statistical analyses

No statistical analyses for this end point

Primary: Number of Participants With Discernible Changes in Electrocardiogram (ECG) Over Time

| | |
|-----------------|---|
| End point title | Number of Participants With Discernible Changes in Electrocardiogram (ECG) Over Time ^[4] |
|-----------------|---|

End point description:

ECG included heart rhythm, heart rate, QRS intervals, QT intervals, RR intervals and corrected QT (QTc) intervals parameters measurement. Any discernible changes in the ECG value over time based on investigator interpretation were reported. The Safety Set included all participants who received at least 1 dose of IP in the SHP647-304 study.

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

From first dose of study drug up to EOS (up to 5.79 years)

Notes:

[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis was planned for this endpoint.

| End point values | UC: Ontamalimab 25 mg | UC: Ontamalimab 25mg then 75 mg | UC: Ontamalimab 75mg | CD: Ontamalimab 25 mg |
|-----------------------------|-----------------------------|--|----------------------------|-----------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 89 | 159 | 268 | 5 |
| Units: participants | 0 | 0 | 0 | 0 |

| End point values | CD: Ontamalimab 25 mg then 75 mg | CD: Ontamalimab 75 mg | | |
|-----------------------------|---|-----------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 10 | 26 | | |
| Units: participants | 0 | 0 | | |

Statistical analyses

No statistical analyses for this end point

Primary: Number of Participants With Discernible Changes in Vital Signs Over Time

| | |
|-----------------|---|
| End point title | Number of Participants With Discernible Changes in Vital Signs Over Time ^[5] |
|-----------------|---|

End point description:

Vital sign assessments included blood pressure, pulse, respiratory rate and temperature. Any discernible changes in vital signs over time per investigator interpretation were reported.

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

From first dose of study drug up to EOS (up to 5.79 years)

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis was planned for this endpoint.

| End point values | UC: Ontamalimab 25 mg | UC: Ontamalimab 25mg then 75 mg | UC: Ontamalimab 75mg | CD: Ontamalimab 25 mg |
|-----------------------------|-----------------------------|--|----------------------------|-----------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 89 | 159 | 268 | 5 |
| Units: participants | 0 | 0 | 0 | 0 |

| End point values | CD: Ontamalimab 25 mg then 75 mg | CD: Ontamalimab 75 mg | | |
|-----------------------------|---|-----------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 10 | 26 | | |
| Units: participants | 0 | 0 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants With Ulcerative Colitis With Treatment Response Over Time

| | |
|-----------------|---|
| End point title | Number of Participants With Ulcerative Colitis With Treatment Response Over Time ^[6] |
|-----------------|---|

End point description:

Treatment response over time=clinical composite score that has decreased by greater than or equal to (≥ 2) points & ≥ 30 percentage (%), with accompanying decrease in sub score for rectal bleeding (RB) ≥ 1 point/subscore for RB ≤ 1 , and/or composite score that has decreased by $\geq 30\%$ & ≥ 3 points compared to baseline value for induction studies. Clinical composite score is measure consisting of sub scores RB(0-3) plus stool frequency(0-3) with higher scores=more severe disease. With implementation of protocol amendment 4 this study became a single arm study with all participants receiving 75 mg ontamalimab. Hence, only those UC participants who were receiving 75 mg ontamalimab Q4W & participating in amendment 4 were analyzed. Full Analysis Set (FAS) included all participants in the randomised set who received at least 1 dose of IP in the SHP647-304 study. Number of subjects analysed is the number of UC participants with data available for analyses.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Up to 5.79 years

Notes:

[6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: With the implementation of amendment 4 of the protocol the study became a single arm study with all participants receiving the 75 mg dose of ontamalimab. Hence, only those UC participants who were receiving the 75 mg dose of ontamalimab every 4 weeks and participating in amendment 4 of the protocol were analyzed in this outcome measure.

| End point values | UC: Ontamalimab 25mg then 75 mg | UC: Ontamalimab 75mg | | |
|-----------------------------|--|----------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 120 | 133 | | |
| Units: participants | 116 | 129 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants With Crohn's Disease With Treatment Response Over Time

| | |
|-----------------|--|
| End point title | Number of Participants With Crohn's Disease With Treatment Response Over Time ^[7] |
|-----------------|--|

End point description:

Treatment response over time=Crohn's Disease Activity Index(CDAI)score that has decreased \geq 100 points and/or simple endoscopic score for Crohn's disease(SES-CD)that has decreased by \geq 25%,both compared to baseline value for induction studies.SES-CD is simple scoring system with 4 endoscopic variables measured in same 5 ileocolonic segments as CD index of severity. Overall values on SES-CD range from 0-56,higher values=more severe disease.4 endoscopic variables are scored from 0-3 in each bowel segment:ileum,right/transverse/left colon,rectum. Presence & size of ulcers(none=0;diameter 0.1-0.5centimeter(cm)=1;0.5-2cm=2;>2cm=3);extent of ulcerated surface(none=0;<10%=1;10%-30%=2; >30%= 3);extent of affected surface(none=0;<50%=1;50%-75%=2;>75%=3);Presence & type of narrowing (none=0;single can be passed=1;multiple can be passed=2;cannot be passed=3). Only those CD participants who were part of arm groups that began receiving ontamalimab 75mg, Q4W,were analysed in this outcome measure.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Up to 5.79 years

Notes:

[7] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: With implementation of protocol amendment 4 this became a single arm study with all participants receiving 75 mg ontamalimab. Hence, only those CD participants who were receiving ontamalimab 75mg Q4W and participating in amendment 4 of the protocol were analyzed.

| End point values | CD: Ontamalimab 25 mg then 75 mg | CD: Ontamalimab 75 mg | | |
|-----------------------------|---|-----------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 6 | 13 | | |
| Units: participants | 6 | 12 | | |

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

From first dose of study drug up to EOS (up to 5.79 years)

Adverse event reporting additional description:

Safety Set included all participants who received at least 1 dose of IP in the SHP647-304 study.

| | |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

Dictionary used

| | |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

| | |
|--------------------|------|
| Dictionary version | 19.1 |
|--------------------|------|

Reporting groups

| | |
|-----------------------|-----------------------|
| Reporting group title | UC: Ontamalimab 25 mg |
|-----------------------|-----------------------|

Reporting group description:

Participants received 25 mg of ontamalimab solution for injection SC, Q4W, for up to 3 years.

| | |
|-----------------------|---------------------------------|
| Reporting group title | UC: Ontamalimab 25mg then 75 mg |
|-----------------------|---------------------------------|

Reporting group description:

Participants received 25 mg of ontamalimab solution for injection SC, Q4W, and later progressed to receive 75 mg in a similar manner for up to 5.79 years.

| | |
|-----------------------|-----------------------|
| Reporting group title | CD: Ontamalimab 75 mg |
|-----------------------|-----------------------|

Reporting group description:

Participants received 75 mg of ontamalimab solution for injection SC, Q4W, for up to 5.79 years.

| | |
|-----------------------|-----------------------|
| Reporting group title | CD: Ontamalimab 25 mg |
|-----------------------|-----------------------|

Reporting group description:

Participants received 25 mg of ontamalimab solution for injection SC, Q4W, for up to 3 years.

| | |
|-----------------------|----------------------------------|
| Reporting group title | CD: Ontamalimab 25 mg then 75 mg |
|-----------------------|----------------------------------|

Reporting group description:

Participants received 25 mg of ontamalimab solution for injection SC, Q4W, and later progressed to receive 75 mg in a similar manner for up to 5.79 years.

| | |
|-----------------------|----------------------|
| Reporting group title | UC: Ontamalimab 75mg |
|-----------------------|----------------------|

Reporting group description:

Participants received 75 mg of ontamalimab solution for injection SC, Q4W, for up to 5.79 years.

| Serious adverse events | UC: Ontamalimab 25 mg | UC: Ontamalimab 25mg then 75 mg | CD: Ontamalimab 75 mg |
|---|-----------------------|---------------------------------|-----------------------|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 15 / 89 (16.85%) | 21 / 159 (13.21%) | 4 / 26 (15.38%) |
| number of deaths (all causes) | 0 | 0 | 0 |
| number of deaths resulting from adverse events | 0 | 0 | 0 |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Acoustic neuroma | | | |
| subjects affected / exposed | 0 / 89 (0.00%) | 0 / 159 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|--|----------------|-----------------|----------------|
| Bladder neoplasm | | | |
| subjects affected / exposed | 0 / 89 (0.00%) | 0 / 159 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Melanocytic naevus | | | |
| subjects affected / exposed | 0 / 89 (0.00%) | 0 / 159 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Fibroadenoma of breast | | | |
| subjects affected / exposed | 0 / 89 (0.00%) | 0 / 159 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Prostate cancer | | | |
| subjects affected / exposed | 0 / 89 (0.00%) | 1 / 159 (0.63%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Uterine leiomyoma | | | |
| subjects affected / exposed | 0 / 89 (0.00%) | 0 / 159 (0.00%) | 1 / 26 (3.85%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal neoplasm | | | |
| subjects affected / exposed | 0 / 89 (0.00%) | 0 / 159 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vascular disorders | | | |
| Vena cava thrombosis | | | |
| subjects affected / exposed | 0 / 89 (0.00%) | 0 / 159 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| General disorders and administration site conditions | | | |
| Chest pain | | | |
| subjects affected / exposed | 0 / 89 (0.00%) | 1 / 159 (0.63%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|----------------|-----------------|----------------|
| Death | | | |
| subjects affected / exposed | 0 / 89 (0.00%) | 0 / 159 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Reproductive system and breast disorders | | | |
| Uterine polyp | | | |
| subjects affected / exposed | 0 / 89 (0.00%) | 1 / 159 (0.63%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Bronchiectasis | | | |
| subjects affected / exposed | 0 / 89 (0.00%) | 0 / 159 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pulmonary embolism | | | |
| subjects affected / exposed | 0 / 89 (0.00%) | 1 / 159 (0.63%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory failure | | | |
| subjects affected / exposed | 0 / 89 (0.00%) | 0 / 159 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Injury, poisoning and procedural complications | | | |
| Fibula fracture | | | |
| subjects affected / exposed | 0 / 89 (0.00%) | 1 / 159 (0.63%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hip fracture | | | |
| subjects affected / exposed | 0 / 89 (0.00%) | 0 / 159 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Joint dislocation | | | |

| | | | |
|---|----------------|-----------------|----------------|
| subjects affected / exposed | 0 / 89 (0.00%) | 1 / 159 (0.63%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Spinal compression fracture | | | |
| subjects affected / exposed | 0 / 89 (0.00%) | 0 / 159 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Tendon injury | | | |
| subjects affected / exposed | 0 / 89 (0.00%) | 0 / 159 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Wound dehiscence | | | |
| subjects affected / exposed | 0 / 89 (0.00%) | 1 / 159 (0.63%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac disorders | | | |
| Atrial fibrillation | | | |
| subjects affected / exposed | 0 / 89 (0.00%) | 1 / 159 (0.63%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Angina unstable | | | |
| subjects affected / exposed | 0 / 89 (0.00%) | 1 / 159 (0.63%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Angina pectoris | | | |
| subjects affected / exposed | 0 / 89 (0.00%) | 1 / 159 (0.63%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Myocardial infarction | | | |
| subjects affected / exposed | 1 / 89 (1.12%) | 0 / 159 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nervous system disorders | | | |

| | | | |
|---|----------------|-----------------|----------------|
| Ischaemic stroke | | | |
| subjects affected / exposed | 0 / 89 (0.00%) | 1 / 159 (0.63%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cerebrovascular accident | | | |
| subjects affected / exposed | 0 / 89 (0.00%) | 0 / 159 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 0 / 89 (0.00%) | 2 / 159 (1.26%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Anaemia macrocytic | | | |
| subjects affected / exposed | 0 / 89 (0.00%) | 0 / 159 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Iron deficiency anaemia | | | |
| subjects affected / exposed | 0 / 89 (0.00%) | 0 / 159 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Eye disorders | | | |
| Uveitis | | | |
| subjects affected / exposed | 0 / 89 (0.00%) | 0 / 159 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal disorders | | | |
| Abdominal pain upper | | | |
| subjects affected / exposed | 0 / 89 (0.00%) | 0 / 159 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Anal fissure | | | |

| | | | |
|---|----------------|-----------------|----------------|
| subjects affected / exposed | 0 / 89 (0.00%) | 1 / 159 (0.63%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Colitis | | | |
| subjects affected / exposed | 0 / 89 (0.00%) | 0 / 159 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Anal fistula | | | |
| subjects affected / exposed | 0 / 89 (0.00%) | 0 / 159 (0.00%) | 1 / 26 (3.85%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Colitis ulcerative | | | |
| subjects affected / exposed | 6 / 89 (6.74%) | 3 / 159 (1.89%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 1 / 8 | 0 / 3 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Enterocolitis | | | |
| subjects affected / exposed | 0 / 89 (0.00%) | 0 / 159 (0.00%) | 1 / 26 (3.85%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Diarrhoea | | | |
| subjects affected / exposed | 0 / 89 (0.00%) | 0 / 159 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Colon dysplasia | | | |
| subjects affected / exposed | 1 / 89 (1.12%) | 0 / 159 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Haemorrhoidal haemorrhage | | | |
| subjects affected / exposed | 0 / 89 (0.00%) | 0 / 159 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Intestinal obstruction | | | |

| | | | |
|---|----------------|-----------------|----------------|
| subjects affected / exposed | 0 / 89 (0.00%) | 1 / 159 (0.63%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Inguinal hernia | | | |
| subjects affected / exposed | 0 / 89 (0.00%) | 0 / 159 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lower gastrointestinal haemorrhage | | | |
| subjects affected / exposed | 0 / 89 (0.00%) | 0 / 159 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Proctitis | | | |
| subjects affected / exposed | 0 / 89 (0.00%) | 1 / 159 (0.63%) | 1 / 26 (3.85%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatobiliary disorders | | | |
| Cholecystitis acute | | | |
| subjects affected / exposed | 1 / 89 (1.12%) | 0 / 159 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cholelithiasis | | | |
| subjects affected / exposed | 0 / 89 (0.00%) | 1 / 159 (0.63%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Skin and subcutaneous tissue disorders | | | |
| Rash generalised | | | |
| subjects affected / exposed | 0 / 89 (0.00%) | 1 / 159 (0.63%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Drug eruption | | | |
| subjects affected / exposed | 0 / 89 (0.00%) | 0 / 159 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urticaria chronic | | | |

| | | | |
|---|----------------|-----------------|----------------|
| subjects affected / exposed | 0 / 89 (0.00%) | 1 / 159 (0.63%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal and urinary disorders | | | |
| Calculus urinary | | | |
| subjects affected / exposed | 0 / 89 (0.00%) | 1 / 159 (0.63%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal colic | | | |
| subjects affected / exposed | 0 / 89 (0.00%) | 0 / 159 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Tubulointerstitial nephritis | | | |
| subjects affected / exposed | 0 / 89 (0.00%) | 0 / 159 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Musculoskeletal and connective tissue disorders | | | |
| Ankylosing spondylitis | | | |
| subjects affected / exposed | 1 / 89 (1.12%) | 0 / 159 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Intervertebral disc degeneration | | | |
| subjects affected / exposed | 0 / 89 (0.00%) | 0 / 159 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infections and infestations | | | |
| Anal abscess | | | |
| subjects affected / exposed | 0 / 89 (0.00%) | 0 / 159 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Appendicitis | | | |
| subjects affected / exposed | 1 / 89 (1.12%) | 1 / 159 (0.63%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|----------------|-----------------|----------------|
| Cellulitis | | | |
| subjects affected / exposed | 0 / 89 (0.00%) | 0 / 159 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Chronic sinusitis | | | |
| subjects affected / exposed | 0 / 89 (0.00%) | 1 / 159 (0.63%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Clostridium difficile colitis | | | |
| subjects affected / exposed | 0 / 89 (0.00%) | 0 / 159 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cytomegalovirus gastrointestinal infection | | | |
| subjects affected / exposed | 0 / 89 (0.00%) | 0 / 159 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Corona virus infection | | | |
| subjects affected / exposed | 0 / 89 (0.00%) | 1 / 159 (0.63%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Herpes zoster | | | |
| subjects affected / exposed | 1 / 89 (1.12%) | 0 / 159 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infection | | | |
| subjects affected / exposed | 0 / 89 (0.00%) | 0 / 159 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lung abscess | | | |
| subjects affected / exposed | 0 / 89 (0.00%) | 0 / 159 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Perirectal abscess | | | |

| | | | |
|---|----------------|-----------------|----------------|
| subjects affected / exposed | 1 / 89 (1.12%) | 0 / 159 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Peritonitis | | | |
| subjects affected / exposed | 0 / 89 (0.00%) | 0 / 159 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonia | | | |
| subjects affected / exposed | 0 / 89 (0.00%) | 0 / 159 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonia viral | | | |
| subjects affected / exposed | 1 / 89 (1.12%) | 1 / 159 (0.63%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Tonsillitis | | | |
| subjects affected / exposed | 0 / 89 (0.00%) | 0 / 159 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Subcutaneous abscess | | | |
| subjects affected / exposed | 1 / 89 (1.12%) | 0 / 159 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metabolism and nutrition disorders | | | |
| Obesity | | | |
| subjects affected / exposed | 0 / 89 (0.00%) | 1 / 159 (0.63%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| Serious adverse events | CD: Ontamalimab 25 mg | CD: Ontamalimab 25 mg then 75 mg | UC: Ontamalimab 75mg |
|---|-----------------------|----------------------------------|----------------------|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 2 / 5 (40.00%) | 2 / 10 (20.00%) | 46 / 268 (17.16%) |
| number of deaths (all causes) | 1 | 0 | 3 |
| number of deaths resulting from adverse events | 1 | 0 | 2 |

| | | | |
|---|---------------|-----------------|-----------------|
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Acoustic neuroma | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 10 (10.00%) | 0 / 268 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bladder neoplasm | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 10 (0.00%) | 1 / 268 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Melanocytic naevus | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 10 (0.00%) | 1 / 268 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Fibroadenoma of breast | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 10 (0.00%) | 1 / 268 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Prostate cancer | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 10 (0.00%) | 0 / 268 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Uterine leiomyoma | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 10 (0.00%) | 1 / 268 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal neoplasm | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 10 (0.00%) | 1 / 268 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vascular disorders | | | |
| Vena cava thrombosis | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 10 (0.00%) | 1 / 268 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|--|----------------|----------------|-----------------|
| General disorders and administration site conditions | | | |
| Chest pain | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 10 (0.00%) | 0 / 268 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Death | | | |
| subjects affected / exposed | 1 / 5 (20.00%) | 0 / 10 (0.00%) | 1 / 268 (0.37%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 1 |
| Reproductive system and breast disorders | | | |
| Uterine polyp | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 10 (0.00%) | 0 / 268 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Bronchiectasis | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 10 (0.00%) | 1 / 268 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| Pulmonary embolism | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 10 (0.00%) | 2 / 268 (0.75%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory failure | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 10 (0.00%) | 1 / 268 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Injury, poisoning and procedural complications | | | |
| Fibula fracture | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 10 (0.00%) | 0 / 268 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hip fracture | | | |

| | | | |
|---|---------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 10 (0.00%) | 1 / 268 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Joint dislocation | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 10 (0.00%) | 0 / 268 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Spinal compression fracture | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 10 (0.00%) | 1 / 268 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Tendon injury | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 10 (10.00%) | 0 / 268 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Wound dehiscence | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 10 (0.00%) | 0 / 268 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac disorders | | | |
| Atrial fibrillation | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 10 (0.00%) | 0 / 268 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Angina unstable | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 10 (0.00%) | 0 / 268 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Angina pectoris | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 10 (0.00%) | 0 / 268 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Myocardial infarction | | | |

| | | | |
|---|---------------|----------------|-----------------|
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 10 (0.00%) | 0 / 268 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nervous system disorders | | | |
| Ischaemic stroke | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 10 (0.00%) | 1 / 268 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cerebrovascular accident | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 10 (0.00%) | 1 / 268 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 10 (0.00%) | 4 / 268 (1.49%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 4 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Anaemia macrocytic | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 10 (0.00%) | 1 / 268 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 2 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Iron deficiency anaemia | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 10 (0.00%) | 1 / 268 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Eye disorders | | | |
| Uveitis | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 10 (0.00%) | 1 / 268 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal disorders | | | |
| Abdominal pain upper | | | |

| | | | |
|---|---------------|----------------|------------------|
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 10 (0.00%) | 1 / 268 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Anal fissure | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 10 (0.00%) | 0 / 268 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Colitis | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 10 (0.00%) | 1 / 268 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Anal fistula | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 10 (0.00%) | 0 / 268 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Colitis ulcerative | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 10 (0.00%) | 10 / 268 (3.73%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 4 / 11 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Enterocolitis | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 10 (0.00%) | 0 / 268 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Diarrhoea | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 10 (0.00%) | 1 / 268 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Colon dysplasia | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 10 (0.00%) | 0 / 268 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Haemorrhoidal haemorrhage | | | |

| | | | |
|---|---------------|----------------|-----------------|
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 10 (0.00%) | 1 / 268 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Intestinal obstruction | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 10 (0.00%) | 0 / 268 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Inguinal hernia | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 10 (0.00%) | 1 / 268 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lower gastrointestinal haemorrhage | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 10 (0.00%) | 1 / 268 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 2 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Proctitis | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 10 (0.00%) | 1 / 268 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatobiliary disorders | | | |
| Cholecystitis acute | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 10 (0.00%) | 1 / 268 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cholelithiasis | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 10 (0.00%) | 1 / 268 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Skin and subcutaneous tissue disorders | | | |
| Rash generalised | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 10 (0.00%) | 0 / 268 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Drug eruption | | | |

| | | | |
|---|----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 5 (20.00%) | 0 / 10 (0.00%) | 0 / 268 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urticaria chronic | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 10 (0.00%) | 0 / 268 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal and urinary disorders | | | |
| Calculus urinary | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 10 (10.00%) | 0 / 268 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal colic | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 10 (10.00%) | 0 / 268 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Tubulointerstitial nephritis | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 10 (0.00%) | 1 / 268 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Musculoskeletal and connective tissue disorders | | | |
| Ankylosing spondylitis | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 10 (0.00%) | 0 / 268 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Intervertebral disc degeneration | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 10 (0.00%) | 1 / 268 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infections and infestations | | | |
| Anal abscess | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 10 (0.00%) | 1 / 268 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|---------------|----------------|-----------------|
| Appendicitis | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 10 (0.00%) | 4 / 268 (1.49%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 4 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cellulitis | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 10 (0.00%) | 1 / 268 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Chronic sinusitis | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 10 (0.00%) | 0 / 268 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Clostridium difficile colitis | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 10 (0.00%) | 1 / 268 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cytomegalovirus gastrointestinal infection | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 10 (0.00%) | 1 / 268 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Corona virus infection | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 10 (0.00%) | 2 / 268 (0.75%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Herpes zoster | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 10 (0.00%) | 0 / 268 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infection | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 10 (0.00%) | 1 / 268 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lung abscess | | | |

| | | | |
|---|---------------|----------------|-----------------|
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 10 (0.00%) | 1 / 268 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Perirectal abscess | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 10 (0.00%) | 0 / 268 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Peritonitis | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 10 (0.00%) | 1 / 268 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonia | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 10 (0.00%) | 3 / 268 (1.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 3 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonia viral | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 10 (0.00%) | 3 / 268 (1.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 3 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Tonsillitis | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 10 (0.00%) | 1 / 268 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Subcutaneous abscess | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 10 (0.00%) | 0 / 268 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metabolism and nutrition disorders | | | |
| Obesity | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 10 (0.00%) | 0 / 268 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

Frequency threshold for reporting non-serious adverse events: 5 %

| Non-serious adverse events | UC: Ontamalimab 25 mg | UC: Ontamalimab 25mg then 75 mg | CD: Ontamalimab 75 mg |
|---|--------------------------|------------------------------------|--------------------------|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 47 / 89 (52.81%) | 109 / 159 (68.55%) | 14 / 26 (53.85%) |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Colon adenoma | | | |
| subjects affected / exposed | 0 / 89 (0.00%) | 1 / 159 (0.63%) | 0 / 26 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Vascular disorders | | | |
| Hypertension | | | |
| subjects affected / exposed | 3 / 89 (3.37%) | 12 / 159 (7.55%) | 0 / 26 (0.00%) |
| occurrences (all) | 3 | 12 | 0 |
| General disorders and administration site conditions | | | |
| Pyrexia | | | |
| subjects affected / exposed | 4 / 89 (4.49%) | 9 / 159 (5.66%) | 1 / 26 (3.85%) |
| occurrences (all) | 8 | 10 | 2 |
| Immune system disorders | | | |
| Rubber sensitivity | | | |
| subjects affected / exposed | 0 / 89 (0.00%) | 0 / 159 (0.00%) | 0 / 26 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Reproductive system and breast disorders | | | |
| Breast pain | | | |
| subjects affected / exposed | 0 / 89 (0.00%) | 1 / 159 (0.63%) | 0 / 26 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Asthma-chronic obstructive pulmonary disease overlap syndrome | | | |
| subjects affected / exposed | 0 / 89 (0.00%) | 0 / 159 (0.00%) | 0 / 26 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oropharyngeal pain | | | |
| subjects affected / exposed | 0 / 89 (0.00%) | 9 / 159 (5.66%) | 0 / 26 (0.00%) |
| occurrences (all) | 0 | 11 | 0 |
| Psychiatric disorders | | | |
| Insomnia | | | |

| | | | |
|---|---------------------|-------------------------|----------------------|
| subjects affected / exposed occurrences (all) | 1 / 89 (1.12%) 1 | 2 / 159 (1.26%) 2 | 0 / 26 (0.00%) 0 |
| Anxiety disorder subjects affected / exposed occurrences (all) | 0 / 89 (0.00%) 0 | 0 / 159 (0.00%) 0 | 0 / 26 (0.00%) 0 |
| Investigations C-reactive protein increased subjects affected / exposed occurrences (all) | 0 / 89 (0.00%) 0 | 2 / 159 (1.26%) 2 | 0 / 26 (0.00%) 0 |
| Blood pressure increased subjects affected / exposed occurrences (all) | 0 / 89 (0.00%) 0 | 1 / 159 (0.63%) 1 | 0 / 26 (0.00%) 0 |
| Nervous system disorders Dizziness subjects affected / exposed occurrences (all) | 1 / 89 (1.12%) 1 | 3 / 159 (1.89%) 3 | 0 / 26 (0.00%) 0 |
| Migraine subjects affected / exposed occurrences (all) | 0 / 89 (0.00%) 0 | 2 / 159 (1.26%) 2 | 0 / 26 (0.00%) 0 |
| Headache subjects affected / exposed occurrences (all) | 3 / 89 (3.37%) 3 | 16 / 159 (10.06%) 23 | 3 / 26 (11.54%) 3 |
| Blood and lymphatic system disorders Anaemia subjects affected / exposed occurrences (all) | 7 / 89 (7.87%) 7 | 14 / 159 (8.81%) 22 | 1 / 26 (3.85%) 1 |
| Leukopenia subjects affected / exposed occurrences (all) | 0 / 89 (0.00%) 0 | 0 / 159 (0.00%) 0 | 2 / 26 (7.69%) 2 |
| Eye disorders Eyelid rash subjects affected / exposed occurrences (all) | 0 / 89 (0.00%) 0 | 0 / 159 (0.00%) 0 | 0 / 26 (0.00%) 0 |
| Uveitis subjects affected / exposed occurrences (all) | 0 / 89 (0.00%) 0 | 0 / 159 (0.00%) 0 | 0 / 26 (0.00%) 0 |
| Optic nerve disorder | | | |

| | | | |
|--|---------------------|----------------------|---------------------|
| subjects affected / exposed occurrences (all) | 0 / 89 (0.00%) 0 | 0 / 159 (0.00%) 0 | 0 / 26 (0.00%) 0 |
| Gastrointestinal disorders | | | |
| Diarrhoea | | | |
| subjects affected / exposed | 3 / 89 (3.37%) | 17 / 159 (10.69%) | 1 / 26 (3.85%) |
| occurrences (all) | 4 | 25 | 1 |
| Dental caries | | | |
| subjects affected / exposed | 1 / 89 (1.12%) | 0 / 159 (0.00%) | 1 / 26 (3.85%) |
| occurrences (all) | 1 | 0 | 1 |
| Crohn's disease | | | |
| subjects affected / exposed | 0 / 89 (0.00%) | 0 / 159 (0.00%) | 3 / 26 (11.54%) |
| occurrences (all) | 0 | 0 | 4 |
| Constipation | | | |
| subjects affected / exposed | 0 / 89 (0.00%) | 1 / 159 (0.63%) | 0 / 26 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Colitis ulcerative | | | |
| subjects affected / exposed | 22 / 89 (24.72%) | 21 / 159 (13.21%) | 0 / 26 (0.00%) |
| occurrences (all) | 29 | 27 | 0 |
| Anal fistula | | | |
| subjects affected / exposed | 1 / 89 (1.12%) | 1 / 159 (0.63%) | 3 / 26 (11.54%) |
| occurrences (all) | 1 | 1 | 4 |
| Abdominal pain | | | |
| subjects affected / exposed | 2 / 89 (2.25%) | 11 / 159 (6.92%) | 2 / 26 (7.69%) |
| occurrences (all) | 2 | 18 | 2 |
| Dry mouth | | | |
| subjects affected / exposed | 0 / 89 (0.00%) | 0 / 159 (0.00%) | 0 / 26 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tongue blistering | | | |
| subjects affected / exposed | 0 / 89 (0.00%) | 0 / 159 (0.00%) | 0 / 26 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Irritable bowel syndrome | | | |
| subjects affected / exposed | 1 / 89 (1.12%) | 1 / 159 (0.63%) | 1 / 26 (3.85%) |
| occurrences (all) | 2 | 1 | 1 |
| Frequent bowel movements | | | |
| subjects affected / exposed | 1 / 89 (1.12%) | 3 / 159 (1.89%) | 0 / 26 (0.00%) |
| occurrences (all) | 1 | 4 | 0 |

| | | | |
|--|---------------------|------------------------|---------------------|
| Dyspepsia subjects affected / exposed occurrences (all) | 2 / 89 (2.25%) 2 | 10 / 159 (6.29%) 16 | 1 / 26 (3.85%) 1 |
| Nausea subjects affected / exposed occurrences (all) | 0 / 89 (0.00%) 0 | 11 / 159 (6.92%) 13 | 0 / 26 (0.00%) 0 |
| Skin and subcutaneous tissue disorders | | | |
| Eczema subjects affected / exposed occurrences (all) | 0 / 89 (0.00%) 0 | 2 / 159 (1.26%) 2 | 0 / 26 (0.00%) 0 |
| Night sweats subjects affected / exposed occurrences (all) | 0 / 89 (0.00%) 0 | 0 / 159 (0.00%) 0 | 0 / 26 (0.00%) 0 |
| Musculoskeletal and connective tissue disorders | | | |
| Pain in extremity subjects affected / exposed occurrences (all) | 0 / 89 (0.00%) 0 | 4 / 159 (2.52%) 4 | 1 / 26 (3.85%) 1 |
| Back pain subjects affected / exposed occurrences (all) | 1 / 89 (1.12%) 2 | 11 / 159 (6.92%) 18 | 1 / 26 (3.85%) 1 |
| Arthritis enteropathic subjects affected / exposed occurrences (all) | 0 / 89 (0.00%) 0 | 0 / 159 (0.00%) 0 | 0 / 26 (0.00%) 0 |
| Arthralgia subjects affected / exposed occurrences (all) | 3 / 89 (3.37%) 3 | 10 / 159 (6.29%) 14 | 1 / 26 (3.85%) 1 |
| Infections and infestations | | | |
| Anal abscess subjects affected / exposed occurrences (all) | 0 / 89 (0.00%) 0 | 0 / 159 (0.00%) 0 | 1 / 26 (3.85%) 2 |
| Influenza subjects affected / exposed occurrences (all) | 2 / 89 (2.25%) 2 | 5 / 159 (3.14%) 5 | 0 / 26 (0.00%) 0 |
| Gastroenteritis subjects affected / exposed occurrences (all) | 0 / 89 (0.00%) 0 | 8 / 159 (5.03%) 8 | 1 / 26 (3.85%) 2 |

| | | | |
|-----------------------------------|----------------|-------------------|-----------------|
| Diverticulitis | | | |
| subjects affected / exposed | 0 / 89 (0.00%) | 0 / 159 (0.00%) | 2 / 26 (7.69%) |
| occurrences (all) | 0 | 0 | 4 |
| Corona virus infection | | | |
| subjects affected / exposed | 2 / 89 (2.25%) | 40 / 159 (25.16%) | 4 / 26 (15.38%) |
| occurrences (all) | 2 | 46 | 4 |
| Bronchitis | | | |
| subjects affected / exposed | 0 / 89 (0.00%) | 9 / 159 (5.66%) | 0 / 26 (0.00%) |
| occurrences (all) | 0 | 10 | 0 |
| Nasopharyngitis | | | |
| subjects affected / exposed | 2 / 89 (2.25%) | 18 / 159 (11.32%) | 3 / 26 (11.54%) |
| occurrences (all) | 2 | 23 | 6 |
| Sinusitis | | | |
| subjects affected / exposed | 0 / 89 (0.00%) | 6 / 159 (3.77%) | 1 / 26 (3.85%) |
| occurrences (all) | 0 | 10 | 1 |
| Respiratory tract infection viral | | | |
| subjects affected / exposed | 1 / 89 (1.12%) | 3 / 159 (1.89%) | 0 / 26 (0.00%) |
| occurrences (all) | 1 | 3 | 0 |
| Respiratory tract infection | | | |
| subjects affected / exposed | 1 / 89 (1.12%) | 4 / 159 (2.52%) | 0 / 26 (0.00%) |
| occurrences (all) | 1 | 4 | 0 |
| Pyelonephritis acute | | | |
| subjects affected / exposed | 0 / 89 (0.00%) | 0 / 159 (0.00%) | 0 / 26 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pharyngitis | | | |
| subjects affected / exposed | 3 / 89 (3.37%) | 2 / 159 (1.26%) | 0 / 26 (0.00%) |
| occurrences (all) | 3 | 2 | 0 |
| Tooth abscess | | | |
| subjects affected / exposed | 0 / 89 (0.00%) | 2 / 159 (1.26%) | 0 / 26 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Upper respiratory tract infection | | | |
| subjects affected / exposed | 3 / 89 (3.37%) | 9 / 159 (5.66%) | 1 / 26 (3.85%) |
| occurrences (all) | 3 | 15 | 1 |
| Viral pharyngitis | | | |
| subjects affected / exposed | 0 / 89 (0.00%) | 0 / 159 (0.00%) | 0 / 26 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|---|---------------------|----------------------|---------------------|
| Vestibular neuronitis subjects affected / exposed occurrences (all) | 0 / 89 (0.00%) 0 | 0 / 159 (0.00%) 0 | 0 / 26 (0.00%) 0 |
|---|---------------------|----------------------|---------------------|

| Non-serious adverse events | CD: Ontamalimab 25 mg | CD: Ontamalimab 25 mg then 75 mg | UC: Ontamalimab 75mg |
|--|---|--|--|
| Total subjects affected by non-serious adverse events subjects affected / exposed | 3 / 5 (60.00%) | 8 / 10 (80.00%) | 155 / 268 (57.84%) |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) Colon adenoma subjects affected / exposed occurrences (all) | 1 / 5 (20.00%) 1 | 0 / 10 (0.00%) 0 | 0 / 268 (0.00%) 0 |
| Vascular disorders Hypertension subjects affected / exposed occurrences (all) | 0 / 5 (0.00%) 0 | 0 / 10 (0.00%) 0 | 13 / 268 (4.85%) 14 |
| General disorders and administration site conditions Pyrexia subjects affected / exposed occurrences (all) | 0 / 5 (0.00%) 0 | 0 / 10 (0.00%) 0 | 13 / 268 (4.85%) 23 |
| Immune system disorders Rubber sensitivity subjects affected / exposed occurrences (all) | 0 / 5 (0.00%) 0 | 1 / 10 (10.00%) 1 | 0 / 268 (0.00%) 0 |
| Reproductive system and breast disorders Breast pain subjects affected / exposed occurrences (all) | 0 / 5 (0.00%) 0 | 1 / 10 (10.00%) 1 | 0 / 268 (0.00%) 0 |
| Respiratory, thoracic and mediastinal disorders Asthma-chronic obstructive pulmonary disease overlap syndrome subjects affected / exposed occurrences (all) Oropharyngeal pain subjects affected / exposed occurrences (all) | 1 / 5 (20.00%) 1 0 / 5 (0.00%) 0 | 0 / 10 (0.00%) 0 0 / 10 (0.00%) 0 | 0 / 268 (0.00%) 0 5 / 268 (1.87%) 7 |
| Psychiatric disorders | | | |

| | | | |
|---|---------------------|----------------------|------------------------|
| Insomnia subjects affected / exposed occurrences (all) | 0 / 5 (0.00%) 0 | 1 / 10 (10.00%) 1 | 8 / 268 (2.99%) 11 |
| Anxiety disorder subjects affected / exposed occurrences (all) | 0 / 5 (0.00%) 0 | 1 / 10 (10.00%) 1 | 0 / 268 (0.00%) 0 |
| Investigations C-reactive protein increased subjects affected / exposed occurrences (all) | 0 / 5 (0.00%) 0 | 1 / 10 (10.00%) 1 | 3 / 268 (1.12%) 3 |
| Blood pressure increased subjects affected / exposed occurrences (all) | 1 / 5 (20.00%) 1 | 0 / 10 (0.00%) 0 | 1 / 268 (0.37%) 1 |
| Nervous system disorders Dizziness subjects affected / exposed occurrences (all) | 1 / 5 (20.00%) 1 | 0 / 10 (0.00%) 0 | 5 / 268 (1.87%) 5 |
| Migraine subjects affected / exposed occurrences (all) | 0 / 5 (0.00%) 0 | 1 / 10 (10.00%) 1 | 4 / 268 (1.49%) 5 |
| Headache subjects affected / exposed occurrences (all) | 1 / 5 (20.00%) 1 | 1 / 10 (10.00%) 1 | 10 / 268 (3.73%) 22 |
| Blood and lymphatic system disorders Anaemia subjects affected / exposed occurrences (all) | 0 / 5 (0.00%) 0 | 0 / 10 (0.00%) 0 | 16 / 268 (5.97%) 23 |
| Leukopenia subjects affected / exposed occurrences (all) | 0 / 5 (0.00%) 0 | 0 / 10 (0.00%) 0 | 1 / 268 (0.37%) 1 |
| Eye disorders Eyelid rash subjects affected / exposed occurrences (all) | 0 / 5 (0.00%) 0 | 1 / 10 (10.00%) 1 | 0 / 268 (0.00%) 0 |
| Uveitis subjects affected / exposed occurrences (all) | 0 / 5 (0.00%) 0 | 1 / 10 (10.00%) 1 | 0 / 268 (0.00%) 0 |

| | | | |
|--|---------------------|----------------------|-------------------------|
| Optic nerve disorder subjects affected / exposed occurrences (all) | 0 / 5 (0.00%) 0 | 1 / 10 (10.00%) 1 | 0 / 268 (0.00%) 0 |
| Gastrointestinal disorders | | | |
| Diarrhoea subjects affected / exposed occurrences (all) | 0 / 5 (0.00%) 0 | 1 / 10 (10.00%) 1 | 10 / 268 (3.73%) 16 |
| Dental caries subjects affected / exposed occurrences (all) | 1 / 5 (20.00%) 1 | 0 / 10 (0.00%) 0 | 1 / 268 (0.37%) 1 |
| Crohn's disease subjects affected / exposed occurrences (all) | 0 / 5 (0.00%) 0 | 1 / 10 (10.00%) 1 | 0 / 268 (0.00%) 0 |
| Constipation subjects affected / exposed occurrences (all) | 1 / 5 (20.00%) 1 | 0 / 10 (0.00%) 0 | 3 / 268 (1.12%) 4 |
| Colitis ulcerative subjects affected / exposed occurrences (all) | 0 / 5 (0.00%) 0 | 0 / 10 (0.00%) 0 | 28 / 268 (10.45%) 40 |
| Anal fistula subjects affected / exposed occurrences (all) | 0 / 5 (0.00%) 0 | 0 / 10 (0.00%) 0 | 0 / 268 (0.00%) 0 |
| Abdominal pain subjects affected / exposed occurrences (all) | 0 / 5 (0.00%) 0 | 0 / 10 (0.00%) 0 | 8 / 268 (2.99%) 10 |
| Dry mouth subjects affected / exposed occurrences (all) | 0 / 5 (0.00%) 0 | 1 / 10 (10.00%) 1 | 1 / 268 (0.37%) 1 |
| Tongue blistering subjects affected / exposed occurrences (all) | 0 / 5 (0.00%) 0 | 1 / 10 (10.00%) 1 | 0 / 268 (0.00%) 0 |
| Irritable bowel syndrome subjects affected / exposed occurrences (all) | 0 / 5 (0.00%) 0 | 1 / 10 (10.00%) 1 | 0 / 268 (0.00%) 0 |
| Frequent bowel movements | | | |

| | | | |
|---|---------------|-----------------|------------------|
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 10 (10.00%) | 1 / 268 (0.37%) |
| occurrences (all) | 0 | 1 | 1 |
| Dyspepsia | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 10 (10.00%) | 9 / 268 (3.36%) |
| occurrences (all) | 0 | 1 | 11 |
| Nausea | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 10 (0.00%) | 5 / 268 (1.87%) |
| occurrences (all) | 0 | 0 | 6 |
| Skin and subcutaneous tissue disorders | | | |
| Eczema | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 10 (10.00%) | 4 / 268 (1.49%) |
| occurrences (all) | 0 | 1 | 4 |
| Night sweats | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 10 (10.00%) | 1 / 268 (0.37%) |
| occurrences (all) | 0 | 1 | 1 |
| Musculoskeletal and connective tissue disorders | | | |
| Pain in extremity | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 10 (10.00%) | 0 / 268 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Back pain | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 2 / 10 (20.00%) | 10 / 268 (3.73%) |
| occurrences (all) | 0 | 3 | 11 |
| Arthritis enteropathic | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 10 (10.00%) | 0 / 268 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Arthralgia | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 2 / 10 (20.00%) | 13 / 268 (4.85%) |
| occurrences (all) | 0 | 3 | 20 |
| Infections and infestations | | | |
| Anal abscess | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 10 (10.00%) | 0 / 268 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Influenza | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 10 (0.00%) | 16 / 268 (5.97%) |
| occurrences (all) | 0 | 0 | 18 |
| Gastroenteritis | | | |

| | | | |
|-----------------------------------|---------------|-----------------|-------------------|
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 10 (10.00%) | 6 / 268 (2.24%) |
| occurrences (all) | 0 | 1 | 8 |
| Diverticulitis | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 10 (0.00%) | 0 / 268 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Corona virus infection | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 2 / 10 (20.00%) | 57 / 268 (21.27%) |
| occurrences (all) | 0 | 2 | 62 |
| Bronchitis | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 2 / 10 (20.00%) | 8 / 268 (2.99%) |
| occurrences (all) | 0 | 3 | 10 |
| Nasopharyngitis | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 10 (0.00%) | 20 / 268 (7.46%) |
| occurrences (all) | 0 | 0 | 27 |
| Sinusitis | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 2 / 10 (20.00%) | 4 / 268 (1.49%) |
| occurrences (all) | 0 | 2 | 4 |
| Respiratory tract infection viral | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 2 / 10 (20.00%) | 4 / 268 (1.49%) |
| occurrences (all) | 0 | 2 | 6 |
| Respiratory tract infection | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 10 (10.00%) | 4 / 268 (1.49%) |
| occurrences (all) | 0 | 1 | 4 |
| Pyelonephritis acute | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 10 (10.00%) | 0 / 268 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Pharyngitis | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 10 (10.00%) | 9 / 268 (3.36%) |
| occurrences (all) | 0 | 1 | 13 |
| Tooth abscess | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 10 (10.00%) | 0 / 268 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Upper respiratory tract infection | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 10 (0.00%) | 16 / 268 (5.97%) |
| occurrences (all) | 0 | 0 | 19 |
| Viral pharyngitis | | | |

| | | | |
|-----------------------------|---------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 10 (10.00%) | 2 / 268 (0.75%) |
| occurrences (all) | 0 | 2 | 2 |
| Vestibular neuronitis | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 10 (10.00%) | 0 / 268 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|-------------------|---|
| 17 December 2017 | The following changes were made as per Amendment 1: 1. Revised study title to reflect inclusion of participants with Crohn's disease. 2. Updated approximate number of sites and countries in which this study will be conducted. 3. Updated the projected number of participants to reflect inclusion of participants with CD entering from Studies SHP647-305, SHP647-306, and SHP647-307. 4. Added inclusion and exclusion criteria for participants with CD entering from studies SHP647-305, SHP647-306, and SHP647-307. 5. Revised definition of safety analysis set to reflect inclusion of participants with CD entering from Studies SHP647-305, SHP647-306, and SHP647-307. 6. Added definition for FAS. 7. Revised expected duration of study to reflect inclusion of participants with CD. 5. Updated inclusion and exclusion criteria. |
| 14 September 2018 | The following changes were made as per Amendment 2: 1. Added text to clarify that a participant's maximum duration of treatment is expected to be 7 years, subject to local or country requirements. 2. Updated exclusion criteria. 3. Added pregnancy as a reason that a participant may be withdrawn from study treatment. |
| 06 November 2019 | The following changes were made as per Amendment 3: 1. Updated total sample size projected for the enrollment in the study. 2. Added inclusion and exclusion criteria for UC participants entering directly. 3. Added visit numbers to the schedules of assessments. 4. Updated endpoints to reflect inclusion of direct-entry UC participants. |
| 21 September 2020 | The following changes were made as per Amendment 4: 1. Removed direct entry of participants with UC. 2. Changed the safety follow-up period from 16 weeks to 12 weeks. 3. Revised total sample size projection. 4. Updated the number of sites and the countries in which the study will be conducted. 5. Added a secondary objective to evaluate the maintenance of response to long-term treatment with ontamalimab as measured by the clinical composite score (for participants with UC) or CDAI score (for participants with CD) and biomarkers, with or without endoscopy. 6. Updated the time of study completion from approximately 7 years to no more than 3 years (ie, a participant's participation is not expected to extend beyond 2023). 7. Updated inclusion and criteria. |

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported